CN117751144A - 抗cd38抗体、抗cd3抗体和双特异性抗体以及它们的用途 - Google Patents

抗cd38抗体、抗cd3抗体和双特异性抗体以及它们的用途 Download PDF

Info

Publication number
CN117751144A
CN117751144A CN202280053639.9A CN202280053639A CN117751144A CN 117751144 A CN117751144 A CN 117751144A CN 202280053639 A CN202280053639 A CN 202280053639A CN 117751144 A CN117751144 A CN 117751144A
Authority
CN
China
Prior art keywords
seq
nos
antigen
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280053639.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·邱
M-C·冯
M·托尔内塔
B·惠特克
濮瀑
靳英
陈鹏
K·C·权
俞澳
G·M·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Younuojian Biotechnology Co ltd
Original Assignee
Hangzhou Younuojian Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Younuojian Biotechnology Co ltd filed Critical Hangzhou Younuojian Biotechnology Co ltd
Publication of CN117751144A publication Critical patent/CN117751144A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202280053639.9A 2021-08-02 2022-08-02 抗cd38抗体、抗cd3抗体和双特异性抗体以及它们的用途 Pending CN117751144A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163228195P 2021-08-02 2021-08-02
US63/228,195 2021-08-02
PCT/US2022/074409 WO2023015170A2 (en) 2021-08-02 2022-08-02 Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Publications (1)

Publication Number Publication Date
CN117751144A true CN117751144A (zh) 2024-03-22

Family

ID=83049800

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280053639.9A Pending CN117751144A (zh) 2021-08-02 2022-08-02 抗cd38抗体、抗cd3抗体和双特异性抗体以及它们的用途

Country Status (9)

Country Link
US (1) US20250277051A1 (https=)
EP (1) EP4380977A2 (https=)
JP (1) JP2024528935A (https=)
KR (1) KR20240042009A (https=)
CN (1) CN117751144A (https=)
AU (1) AU2022323166A1 (https=)
CA (1) CA3226428A1 (https=)
IL (1) IL310024A (https=)
WO (1) WO2023015170A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119236080A (zh) * 2024-09-29 2025-01-03 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种医药组合物在制备用于治疗多发性硬化药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途
WO2025162453A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体前药及其应用
WO2025201240A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
WO2025201242A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
JP6775422B2 (ja) * 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA43219A (fr) * 2015-11-10 2018-09-19 Univ Medical Center Hamburg Eppendorf Polypeptides de liaison d'antigène dirigés contre cd38
CA3078800A1 (en) * 2017-10-10 2019-04-18 Sanofi Anti-cd38 antibodies and methods of use
BR112021000173A2 (pt) * 2018-10-26 2021-05-04 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd38
CA3144961A1 (en) * 2019-07-01 2021-01-07 Sorrento Therapeutics, Inc. Heterodimeric antibodies that bind to cd38 and cd3

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119236080A (zh) * 2024-09-29 2025-01-03 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种医药组合物在制备用于治疗多发性硬化药物中的应用

Also Published As

Publication number Publication date
WO2023015170A2 (en) 2023-02-09
JP2024528935A (ja) 2024-08-01
EP4380977A2 (en) 2024-06-12
US20250277051A1 (en) 2025-09-04
KR20240042009A (ko) 2024-04-01
IL310024A (en) 2024-03-01
WO2023015170A3 (en) 2023-04-06
CA3226428A1 (en) 2023-02-09
AU2022323166A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
US20250270314A1 (en) Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
JP7591917B2 (ja) Ｓｉｒｐ－アルファドメインまたはそのバリアントを有する構築物
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
US20250277051A1 (en) Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
CA3145387A1 (en) Fusion proteins comprising a ligand-receptor pair and a biologically functional protein
JP2022533538A (ja) Ｔ細胞媒介性免疫を調節するための材料及び方法
WO2015146437A1 (ja) 高機能性ＩｇＧ２型二重特異性抗体
WO2023051727A1 (zh) 结合cd3的抗体及其用途
WO2022081794A1 (en) Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
AU2023212483A1 (en) Immunomodulatory trispecific t cell engager fusion proteins
CA3232216A1 (en) Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
JP7822466B2 (ja) 低減された凝集能及び低減された疎水性を有する、改善されたＦｃサイレンシングされた抗ｏｘＭＩＦ抗体
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
WO2025201242A1 (en) Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
EP4585618A1 (en) Anti-ilt4 antibody and pharmaceutical use thereof
WO2025117641A2 (en) ANTIBODIES TARGETING DISEASE ASSOCIATED ANTIGEN AND γδ T CELL RECEPTORS AND USES THEREOF
WO2025036449A1 (zh) 一种包含免疫缀合物的药物组合物及其用途
WO2025226970A2 (en) Ly6g6d binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof
JP2026506906A (ja) 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
TW202528360A (zh) 藉由重組反應製備異源多聚體的方法
HK1257372B (zh) 具有SIRP-α结构域或其变体的构建体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination